Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LLMC 2020 | The future of multiple myeloma treatment

Joseph Mikhael • 21 Oct 2020
LLMC 2020
Multiple Myeloma Melflufen

Joseph Mikhael, MD, MEd, FRCPC, FACP, Translational Genomics Research Institute (TGen), City of Hope Cancer Center, CA, outlines the future of multiple myeloma (MM) treatment, highlighting the significance of developing drugs with new mechanisms of action, such as anti-BCMA (B-cell maturation antigen) therapies, chimeric antigen receptor (CAR) T-cell therapies and bispecific antibody therapies, and the potential approval of the first CAR T-cell therapy and melphalan flufenamide in the near future. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Disclosures

Consultant for Amgen, BMS, Karyopharm, Janseen, Sanofi and Takeda

More from Joseph Mikhael

2:10
IKEMA trial update: Isatuximab in MM
Joseph Mikhael • 21 Oct 2020
1:53
Transplantation for consolidation in multiple myeloma
Joseph Mikhael • 21 Oct 2020
3:08
Disparities between African American and Caucasian patients with MM
Joseph Mikhael • 21 Oct 2020
2:10
Mentorship in the virtual era
Joseph Mikhael • 21 Oct 2020

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals